Search Videos and More
Fox Chase Researchers Present Data on Integrating Palliative Care Education Into Hematology-Oncology Fellowships
A new integrated palliative care rotation for hematology/oncology fellows improved their palliative care knowledge and skill confidence, according to results of a pilot study presented today by Fox Chase Cancer Center researchers at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.Integration, Location, Innovation: The Fox Chase-Temple Urologic Institute Leads the Way in Care
At Temple Health, we’re no stranger to firsts—whether that means performing a pioneering surgery, opening a new type of facility, or offering a groundbreaking treatment. That’s why it’s no surprise that we’re also leading the way in Urology care, reinforced by the recent launch of the Fox Chase-Temple Urologic Institute.Atlantic Regional Hematopathology Meeting
Presented by Fox Chase Cancer Center and the Temple Health Office for Continuing Medical Education, this in-person education program is designed to focus on the role of molecular pathology and new technologies in diagnosis, prognostic stratification, and treatment of complex cases. Participants will gain insights into the significant changes, updates, and new categories in the 5th Edition of the World Health Organization Classification of Hematolympoid Tumors. Renowned invited pathologists and senior authors of the new WHO edition-Dr. Joseph Khoury, Dr. German Ott, and Dr. Sanam Loghavi-will discuss notable updates, modications, and new classifications in the morphology and molecular genetics of hematologic neoplasms that can be immediately applied in practice. As usual, there will be case-based podium presentations followed by discussion. A poster session will also take place.Fox Chase Researchers Examine Alternative Methods of Specialized Imaging Scans for Kidney Masses
In a study presented today at the American Urological Association (AUA) Annual Meeting 2024, researchers from Fox Chase Cancer Center showed that using numerical cutoffs as opposed to radiologist-read CT scans to determine whether a mass was likely cancerous did not yield more accurate results.Fox Chase Researchers Examine Effects of Radiation Therapy Timing on Lifespan of Artificial Urinary Sphincters
In a study presented today at the American Urological Association (AUA) Annual Meeting 2024, researchers at Fox Chase Cancer Center showed that in men who have undergone surgery for prostate cancer, the function of artificial urinary sphincters for stress urinary incontinence was improved when radiation was used as an adjuvant therapy rather than as a salvage therapy.Putting the Nurse Back into Nurse Navigation
More than 15 years ago, Fox Chase Cancer Center launched a Nurse Navigation system to expedite the journey through complex cancer care with experienced oncologic nurses as a patient’s first 'point-of-contact' via phone.HER2-Targeted Agents: Not Just for Breast Cancer
With 20% of breast cancers driven by alterations to the HER2 gene, inhibiting the expression of this gene has been an objective of researchers and clinicians for decades, and a number of inhibitory therapies have been developed.Harnessing the Power of Adaptive Radiation Therapy: A One-Year Review from Fox Chase Cancer Center
Over the past year, the Fox Chase Cancer Center Radiation Oncology team led by Eric Horwitz, MD, FABS, FASTRO, Chair of the Department of Radiation Oncology at Fox Chase and the Lewis Katz School of Medicine at Temple University, has boldly moved adaptive radiation therapy into the mainstream, demonstrating its clinical advantages for treating prostate, bladder, liver, pancreas, breast, lung, and head and neck cancers.Mapping a Path to Clinical Trials: Bringing Fox Chase’s Innovative Care to the Temple Community
Clinical trials are among the most important resources when it comes to effectively treating challenging cases of cancer, but at Fox Chase Cancer Center, these trials encompass much more than just testing new drug candidates that may be more effective alternative treatments.Fox Chase Fellows – Winter 2024
People say you never really leave Fox Chase. Just ask Matt Zibelman, MD, who was a Fox Chase hematology/oncology fellow and now is the GU Service Line Director of Clinical and Translational Research—or his colleague Mark Hallman, MD, PhD, a former Fox Chase Radiation Oncology resident, now serving as the GU Service Line Clinical DirectorMany Legacies to Carry On
In May 2023, Michael O. Meyers, MD, a surgical oncologist at UNC, was named the James F. and Alice B. Newsome Distinguished Professor.Fox Chase Researcher’s Presentation Highlights Unique Approach to Esophagectomy at American College of Surgeons Clinical Congress
Nosayaba Enofe, MD, presented his experience with a unique minimally invasive hybrid approach to esophagectomy at the American College of Surgeons Clinical Congress.